June 03, 2026
1 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Outlook Therapeutics resubmits biologics license application for ONS-5010
Outlook Therapeutics resubmitted a biologics license application to the FDA for ONS-5010 for the treatment of neovascular age-related macular degeneration, according to a press release. The company successfully appealed a 2025 complete response letter for ONS-5010 (bevacizumab-vikg, bevacizumab gamma), also known as Lytenava, and the FDA confirmed that effectiveness of the treatment has been
368 words~2 min read
